Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Phibro Animal HealthPAHC +2.45%80 Net Margin % is 6.26% as of Mar. 2026, which is 6% above its 10-year median of 5.88. GuruFocus rates PAHC with a GF Score™ of 80/100 and a GF Value™ of $29.49 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Phibro Animal Health ranks better than 52.6% on this metric.
The historical rank and industry rank for Phibro Animal Health's Net Margin % or its related term are showing as below:
PAHC'
s Net Margin % Range Over the Past 10 Years
Min: 0.24 Med: 5.88 Max: 11.01
Current: 6.35
PAHC's Net Margin % is ranked better than 52.6% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.635
vs PAHC: 6.35
Phibro Animal Health (NAS:PAHC) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Phibro Animal Health Net Margin % Related Terms
Phibro Animal Health Net Margin % Historical Data
* Premium members only.
The historical data trend for Phibro Animal Health's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Phibro Animal Health Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Net Margin % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health (PAHC) has a Net Margin % of 6.26% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Phibro Animal Health and its competitors. This is near median its historical median of 5.88. Over the past decade, Phibro Animal Health's Net Margin % has ranged from 0.24 to 11.01. According to the industry distribution chart, Phibro Animal Health ranks #455 out of 960 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is Phibro Animal Health's Net Margin % too high?
Phibro Animal Health's current Net Margin % of 6.26% is near median its 10-year median of 5.88. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 11.01. The Drug Manufacturers industry median Net Margin % is 5.64. Phibro Animal Health's value of 6.26% is 11.1% above this industry median. Based on the distribution chart, Phibro Animal Health ranks #455 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Phibro Animal Health has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Net Margin % compare to ALVO and XERS?
According to the Drug Manufacturers industry distribution chart, Phibro Animal Health ranks #455 out of 960 companies for Net Margin %. This puts Phibro Animal Health in the upper half of its industry. The industry median Net Margin % is 5.64. Phibro Animal Health's value of 6.26% is 11.1% above this benchmark. Historically, Phibro Animal Health's own Net Margin % has ranged from 0.24 to 11.01 over the past decade. While the company's 10-year median is 5.88 vs. the industry median of 5.64, Phibro Animal Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.64, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phibro Animal Health's current Net Margin % of 6.26% is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Phibro Animal Health and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phibro Animal Health's current Net Margin % is 6.26%, which is near median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (PAHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $29.49, compared to a current price of $33.86 — trading 14.8% above its estimated fair value. The current Net Margin % is 6.26%, which is near median its 10-year median of 5.88 and 11.1% above the Drug Manufacturers industry median of 5.64. Phibro Animal Health's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Phibro Animal Health (PAHC), the current Net Margin % is 6.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Phibro Animal Health (PAHC) Overvalued in 2026?
Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued.
The current stock price of $33.86 is trading 14.8% above its estimated GF Value™ of $29.49.
GuruFocus considers Phibro Animal Health to be Modestly Overvalued.
Key valuation signals for PAHC:
Net Margin %: 6.26% (near median its 10-year median of 5.88)
GF Value™: $29.49 vs. price of $33.86 (14.8% above fair value)
Industry Position: 11.1% above the Drug Manufacturers median (#455 of 960)
No single metric tells the full story. See the PAHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
80GF Score
Get the complete analysis for PAHC
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAHC has been successfully added to your 
